Xspray was founded in 2003 as a drug delivery company based on the company’s patented nozzle for particle engineering and scale-up. In 2011, Xspray realigned its business model from conducting contract research and development for other pharmaceutical companies to focusing on developing proprietary drugs based on its RightSize™ technology. Xspray is now a pharmaceutical company focused on developing improved and generic versions of already marketed drugs, mainly protein kinase inhibitors (PKIs) for targeted cancer treatment, and aims to be world leader in this field.
Xspray has announced three product candidates in development, with a clear path to launch the products in the US. The original drugs had in 2019 a yearly sales of over USD 2 billion in the US alone.